Loading organizations...
Elixir Pharmaceuticals was a Cambridge, Massachusetts-based biopharmaceutical company focused on the discovery and development of novel therapeutics for human diseases. Operating within the broader biotechnology sector, the enterprise primarily targeted metabolic disorders and age-related conditions by leveraging advanced genetic research to identify and validate new drug candidates. During its operational lifecycle, the firm secured significant venture capital backing, raising over $40 million in funding from prominent life science investors including MPM Capital, ARCH Venture Partners, and Oxford Bioscience Partners. The company attempted to commercialize treatments targeting the underlying mechanisms of aging, but despite advancing early clinical programs and establishing a specialized research pipeline, the organization could not sustain its business model and ultimately ceased operations. Elixir Pharmaceuticals was officially founded in 2001 by prominent molecular biologists and aging researchers Cynthia Kenyon and Leonard Guarente.
Elixir Pharmaceuticals has raised $84.0M across 3 funding rounds.
Elixir Pharmaceuticals has raised $84.0M in total across 3 funding rounds.
Elixir Pharmaceuticals has raised $84.0M across 3 funding rounds. Most recently, it raised $12.0M Series D in May 2009.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2009 | $12M Series D | — | ARCH Venture Partners | Announced |
| Nov 1, 2006 | $31M Series C | — | ARCH Venture Partners, MPM Capital | Announced |
| Oct 1, 2003 | $41M Series B | — | ARCH Venture Partners | Announced |
Elixir Pharmaceuticals has raised $84.0M in total across 3 funding rounds.
Elixir Pharmaceuticals's investors include ARCH Venture Partners, MPM Capital.
Elixir Pharmaceuticals is a Cambridge, Massachusetts-based biopharmaceutical company founded in 1999 that focused on developing and commercializing drugs to treat and prevent metabolic diseases and age-related diseases.[1] The company raised $169.05M in total funding but is now listed as "Dead" or defunct, with no active operations or recent developments noted in available data.[1] It targeted the healthcare sector, particularly areas like cardio-renal-metabolic conditions, competing with firms such as Intercept Pharmaceuticals and Intarcia Therapeutics.[1]
Note: Search results also reference unrelated entities like Elixir Pharma (Egypt, founded 2018, active in pharmaceuticals for unmet needs)[2] and Elixir Pharmaceuticals Inc (India-based manufacturer).[3] This analysis centers on the U.S. biopharma firm matching the query's technology company description, as it aligns with biotech innovation.
Elixir Pharmaceuticals emerged in 1999 in Cambridge, MA, amid the biotech boom targeting metabolic disorders like diabetes and obesity, which were gaining attention due to rising prevalence.[1] Key details on founders are sparse in records, but the company built a portfolio around small-molecule drugs for metabolic and age-related conditions, raising over $169M from investors to fuel R&D.[1] Early traction included advancing candidates through preclinical and clinical stages, though it ultimately ceased operations, marking a common pivot or shutdown in high-risk biotech ventures.[1]
Elixir rode the late-1990s/early-2000s wave of genomics-driven drug discovery for metabolic diseases, fueled by the Human Genome Project and surging diabetes rates (projected to double globally by 2025).[1] Timing aligned with venture interest in biotech post-dot-com, but high failure rates in clinical trials—over 90% for metabolic drugs—contributed to its demise, reflecting market forces like regulatory hurdles and big pharma acquisitions.[1] It exemplified Cambridge's startup ecosystem, influencing talent flow to survivors like Intarcia, though its shutdown underscores biotech's attrition (only ~10% of ventures succeed long-term).
With "Dead" status confirmed, Elixir Pharmaceuticals has no active future; its IP or team likely absorbed into other ventures, a typical biotech endpoint.[1] Trends like GLP-1 dominance (e.g., Ozempic) validate its metabolic focus, but earlier timing missed mRNA/precision med tech shifts. Its legacy persists in Cambridge's ecosystem, seeding expertise for next-gen firms targeting aging—watch for alumni-led revivals in longevity biotech. This defunct pioneer's story highlights biotech's high-stakes gamble, where bold metabolic bets shape today's $100B+ anti-obesity market.
